Cargando…

Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data

PURPOSE: Treatment with the tyrosine kinase inhibitor (TKI) imatinib in patients with gastrointestinal stromal tumours (GIST) causes symptoms that could negatively impact health-related quality of life (HRQoL). Treatment-related symptoms are usually clinician-reported and little is known about patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	den Hollander, Dide, Dirkson, Anne R., Verberne, Suzan, Kraaij, Wessel, van Oortmerssen, Gerard, Gelderblom, Hans, Oosten, Astrid, Reyners, Anna K. L., Steeghs, Neeltje, van der Graaf, Winette T. A., Desar, Ingrid M. E., Husson, Olga
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046353/ https://www.ncbi.nlm.nih.gov/pubmed/35233640 http://dx.doi.org/10.1007/s00520-022-06929-3

Ejemplares similares

Sample Bias in Web-Based Patient-Generated Health Data of Dutch Patients With Gastrointestinal Stromal Tumor: Survey Study
por: Dirkson, Anne, et al.
Publicado: (2022)

Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data
por: Mohammadi, Mahmoud, et al.
Publicado: (2023)

Automated gathering of real-world data from online patient forums can complement pharmacovigilance for rare cancers
por: Dirkson, Anne, et al.
Publicado: (2022)

Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients
por: Mohammadi, Mahmoud, et al.
Publicado: (2022)

Gastrointestinal Stromal Tumours (GIST) in Young Adult (18–40 Years) Patients: A Report from the Dutch GIST Registry
por: IJzerman, Nikki S., et al.
Publicado: (2020)

Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature
por: van de Wal, Deborah, et al.
Publicado: (2022)

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
por: Westerdijk, Kim, et al.
Publicado: (2020)

Unravelling the heterogeneity of soft tissue and bone sarcoma patients’ health-related quality of life: a systematic literature review with focus on tumour location
por: den Hollander, Dide, et al.
Publicado: (2020)

Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients
por: Verboom, Michiel C., et al.
Publicado: (2019)

Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study
por: Verboom, Michiel C., et al.
Publicado: (2017)

Reintroduction of Imatinib in GIST
por: Reid, T.
Publicado: (2013)

Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure
por: Bins, Sander, et al.
Publicado: (2016)

Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
por: Vincenzi, Bruno, et al.
Publicado: (2022)

‘I thought I had fibroids, and now I don’t’: a mixed method study on health-related quality of life in uterine sarcoma patients
por: den Hollander, Dide, et al.
Publicado: (2022)

The sarcoma diagnostic interval: a systematic review on length, contributing factors and patient outcomes
por: Soomers, Vicky, et al.
Publicado: (2020)

Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010)

Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study
por: Younger, E., et al.
Publicado: (2021)

Sex differences in patients with gastrointestinal stromal tumours: do they exist and does it affect survival?
por: IJzerman, N.S., et al.
Publicado: (2022)

A single digital droplet PCR assay to detect multiple KIT exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors
por: Boonstra, Pieter A., et al.
Publicado: (2018)

Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
por: Tielen, Ronald, et al.
Publicado: (2012)

Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients
por: Schiavon, Gaia, et al.
Publicado: (2012)

Quality of life and experiences of sarcoma trajectories (the QUEST study): protocol for an international observational cohort study on diagnostic pathways of sarcoma patients
por: Soomers, Vicky, et al.
Publicado: (2020)

Metastatic duodenal GIST: role of surgery combined with imatinib mesylate
por: Mohiuddin, Kamran, et al.
Publicado: (2007)

Imatinib plasma levels: correlation with clinical benefit in GIST patients
por: Widmer, N, et al.
Publicado: (2010)

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
por: Cauchi, C., et al.
Publicado: (2011)

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
por: Quek, Richard, et al.
Publicado: (2010)

Liquid Biopsies in Sarcoma Clinical Practice: Where Do We Stand?
por: van der Laan, Pia, et al.
Publicado: (2021)

Psychological and social challenges of patients with locally advanced and metastatic gastrointestinal stromal tumours (GIST) on long-term treatment with tyrosine kinase inhibitors: a qualitative study with patients and medical oncologists
por: van de Wal, Deborah, et al.
Publicado: (2023)

Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells
por: Sako, Hiroyuki, et al.
Publicado: (2014)

Correction: Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients
por: Schiavon, Gaia, et al.
Publicado: (2013)

Health-related quality Of Life In patients with advanced Soft TIssue sarcomas treated with Chemotherapy (The HOLISTIC study): protocol for an international observational cohort study
por: Younger, Eugenie, et al.
Publicado: (2020)

Subcapsular Liver Hematoma in Metastatic GIST Complicating Imatinib (Gleevec) Therapy
por: Shankar, Sridhar
Publicado: (2015)

Imatinib-induced Ototoxicity in a Patient with Gastrointestinal Stromal Tumor (GIST)
por: Wasif, Komal, et al.
Publicado: (2016)

Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?
por: Zhuang, Wei, et al.
Publicado: (2018)

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
por: Tang, Sumin, et al.
Publicado: (2017)

Unraveling the Heterogeneity of Sarcoma Survivors’ Health-Related Quality of Life Regarding Primary Sarcoma Location: Results from the SURVSARC Study
por: van Eck, Ilse, et al.
Publicado: (2020)

Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose
por: Roosendaal, Jeroen, et al.
Publicado: (2020)

New Systemic Therapy Options for Advanced Sarcomas
por: van der Graaf, Winette T. A., et al.
Publicado: (2012)

Imatinib administration in two patients with liver metastases from GIST and severe jaundice
por: De Pas, T, et al.
Publicado: (2003)

Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs)
por: Vetto, John T
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_u28td4qgjcb3qvfnho9bkckou4